Cargando…

Remission of type 2 diabetes following long‐term treatment with injectable testosterone undecanoate in patients with hypogonadism and type 2 diabetes: 11‐year data from a real‐world registry study

AIMS: To investigate whether testosterone therapy (TTh) in men with hypogonadism and type 2 diabetes mellitus (T2DM) improves glycaemic control and insulin sensitivity, and results in remission of T2DM. MATERIAL AND METHODS: A total of 356 men who had total testosterone levels ≤12.1 nmol/L (350 ng/d...

Descripción completa

Detalles Bibliográficos
Autores principales:	Haider, Karim Sultan, Haider, Ahmad, Saad, Farid, Doros, Gheorghe, Hanefeld, Markolf, Dhindsa, Sandeep, Dandona, Paresh, Traish, Abdulmaged
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Blackwell Publishing Ltd 2020
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7689919/ https://www.ncbi.nlm.nih.gov/pubmed/32558149 http://dx.doi.org/10.1111/dom.14122

Ejemplares similares

SUN-083 Hypertension and Hemodynamic Parameters in Men with Hypogonadism Improve Under Long-Term Treatment with Testosterone Undecanoate Injections (TU) Compared to Untreated Hypogonadal Control Patients
por: Saad, Farid, et al.
Publicado: (2019)

MON-091 Profound and Sustained Weight Loss in Men With Hypogonadism and Obesity Receiving Long-Term Testosterone Therapy (TTh) with Testosterone Undecanoate Injections (TU): 10-Year Data from a Registry Study in a Urological Setting
por: Haider, Karim, et al.
Publicado: (2019)

SUN-226 Improvements In Quality Of Life In Men With Hypogonadism Under Long-term Testosterone Therapy (TTh) With Testosterone Undecanoate Injections (TU): Experience From 6,500 Patient-years Ina Registry Study Ina Urological Setting
por: Haider, Karim, et al.
Publicado: (2019)

OR21-2 Lipid Profiles Improve in Men With Hypogonadism and Pre-existing Cardiovascular Disease Under Long-term Testosterone Therapy (TTh) With Testosterone Undecanoate Injections (TU): 10-year Data From a Controlled Registry Study in a Urological Setting
por: Haider, Ahmad, et al.
Publicado: (2019)

SAT-533 Men with Hypogonadism and Osteoporosis Benefit from Long-Term Testosterone Therapy (TTh) with Testosterone Undecanoate Injections (TU) Regardless of Co-Medication with Bisphosphonates: 10-Year Data from a Controlled Registry Study in a Urological Setting
por: Haider, Ahmad, et al.
Publicado: (2019)

SUN-055 Reduction of Mortality and Major Adverse Cardiovascular Events (MACE) in Men with Hypogonadism Treated with Long-Term Testosterone Therapy (TTh) with Testosterone Undecanoate Injections (TU): 10-Year Data from a Registry Study in a Urological Setting
por: Saad, Farid, et al.
Publicado: (2019)

Remission of type 2 diabetes and pleiotropic effects of long-term testosterone treatment for “late-onset” hypogonadism: A case report
por: Haider, Ahmad, et al.
Publicado: (2019)

Long-Term Testosterone Therapy Improves Cardiometabolic Function and Reduces Risk of Cardiovascular Disease in Men with Hypogonadism: A Real-Life Observational Registry Study Setting Comparing Treated and Untreated (Control) Groups
por: Traish, Abdulmaged M., et al.
Publicado: (2017)

Remission of type 2 diabetes in a hypogonadal man under long-term testosterone therapy
por: Haider, Ahmad, et al.
Publicado: (2017)

Effects of Long-Term Testosterone Therapy on Patients with “Diabesity”: Results of Observational Studies of Pooled Analyses in Obese Hypogonadal Men with Type 2 Diabetes
por: Haider, Ahmad, et al.
Publicado: (2014)

Recognizing the True Value of Testosterone Therapy in Health Care
por: Morgentaler, Abraham, et al.
Publicado: (2022)

Progressive Improvement of T-Scores in Men with Osteoporosis and Subnormal Serum Testosterone Levels upon Treatment with Testosterone over Six Years
por: Haider, Ahmad, et al.
Publicado: (2014)

Long-term testosterone therapy in hypogonadal men ameliorates elements of the metabolic syndrome: an observational, long-term registry study
por: Traish, A M, et al.
Publicado: (2014)

Hypogonadal men with moderate-to-severe lower urinary tract symptoms have a more severe cardiometabolic risk profile and benefit more from testosterone therapy than men with mild lower urinary tract symptoms
por: Saad, Farid, et al.
Publicado: (2018)

Low Estradiol Concentrations in Men With Subnormal Testosterone Concentrations and Type 2 Diabetes
por: Dhindsa, Sandeep, et al.
Publicado: (2011)

Increase in Osteocalcin Following Testosterone Therapy in Men With Type 2 Diabetes and Subnormal Free Testosterone
por: Ghanim, Husam, et al.
Publicado: (2019)

Differential effects of 11 years of long-term injectable testosterone undecanoate therapy on anthropometric and metabolic parameters in hypogonadal men with normal weight, overweight and obesity in comparison with untreated controls: real-world data from a controlled registry study
por: Saad, F., et al.
Publicado: (2020)

Optimal injection interval for testosterone undecanoate treatment of hypogonadal and transgender men
por: Shankara Narayana, Nandini, et al.
Publicado: (2021)

Elderly men over 65 years of age with late-onset hypogonadism benefit as much from testosterone treatment as do younger men
por: Saad, Farid, et al.
Publicado: (2015)

A New Oral Testosterone Undecanoate Formulation Restores Testosterone to Normal Concentrations in Hypogonadal Men
por: Swerdloff, Ronald S, et al.
Publicado: (2020)

Testosterone Concentration in Young Patients With Diabetes
por: Chandel, Anil, et al.
Publicado: (2008)

SUN-222 Testosterone Treatment in Men with Classical vs. Functional Hypogonadism: A 9-Year Registry
por: Zitzmann, Michael, et al.
Publicado: (2019)

Effects of the oral testosterone undecanoate Kyzatrex™ on ambulatory blood pressure in hypogonadal men
por: White, William B., et al.
Publicado: (2021)

Corrigendum for: “A New Oral Testosterone Undecanoate Formulation Restores Testosterone to Normal Concentrations in Hypogonadal Men”
Publicado: (2020)

Testosterone therapy in men with testosterone deficiency: Are we beyond the point of no return?
por: Traish, Abdulmaged
Publicado: (2016)

SUN-234 Effect of Testosterone Undecanoate on Metabolic Syndrome Parameters in a Cohort of Hypogonadism
por: Yadav, Subhash Chandra, et al.
Publicado: (2019)

A new oral testosterone undecanoate therapy comes of age for the treatment of hypogonadal men
por: Swerdloff, Ronald S., et al.
Publicado: (2020)

Hypogonadotropic Hypogonadism in Diabesity: Pathogenic Factors and Therapeutic Implications
por: Dandona, Paresh, et al.
Publicado: (2022)

Erratum: Correction of the references for Figures. Testosterone therapy in men with testosterone deficiency: Are we beyond the point of no return?
por: Traish, Abdulmaged
Publicado: (2017)

Safety Analysis of an Oral Testosterone Undecanoate (TU) Formulation Following 2 Years of Administration in Hypogonadal Men
por: Swerdloff, Ronald S, et al.
Publicado: (2021)

Men with testosterone deficiency and a history of cardiovascular diseases benefit from long-term testosterone therapy: observational, real-life data from a registry study
por: Haider, Ahmad, et al.
Publicado: (2016)

Testosterone and weight loss: the evidence
por: Traish, Abdulmaged M.
Publicado: (2014)

Comment on: Wehr et al. Low Free Testosterone Levels Are Associated With All-Cause and Cardiovascular Mortality in Postmenopausal Diabetic Women. Diabetes Care 2011;34:1771–1777
por: Kuhadiya, Nitesh D., et al.
Publicado: (2012)

Corrigendum to a new oral testosterone undecanoate (TU) therapy comes of age for the treatment of hypogonadal men
Publicado: (2021)

Population Pharmacokinetic Modeling and Simulations to Evaluate a Potential Dose Regimen of Testosterone Undecanoate in Hypogonadal Males
por: Pastuszak, Alexander W., et al.
Publicado: (2021)

Cardiovascular benefits and safety profile of acarbose therapy in prediabetes and established type 2 diabetes
por: Hanefeld, Markolf
Publicado: (2007)

Testosterone Concentrations in Diabetic and Nondiabetic Obese Men
por: Dhindsa, Sandeep, et al.
Publicado: (2010)

Impact of Testosterone Deficiency and Testosterone Therapy on Lower Urinary Tract Symptoms in Men with Metabolic Syndrome
por: Traish, Abdulmaged M., et al.
Publicado: (2018)

SUN-LB114 Remission of Type 2 Diabetes (DMT2) in Hypogonadal Men Under Long-Term Testosterone Therapy
por: Mskhalaya, George, et al.
Publicado: (2020)

Insulin Use Early in the Course of Type 2 Diabetes Mellitus: The ORIGIN Trial
por: Hanefeld, Markolf, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_ujrtoknkjlqjvomf9rbvg4jbjn